Phytonadione is not a clotting agent, but overzealous therapy with Phytonadione may restore conditions which originally permitted thromboembolic phenomena.

When Phytonadione is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Whenever possible, administer benzyl alcohol-free formulations in pediatric patients. Interim use of whole blood or component therapy may also be necessary if bleeding is severe. The coagulant effects of Phytonadione are not immediate improvement of INR may take 1-8 hours. Use the lowest effective dose of Phytonadione. Monitor international normalized ratio (INR) regularly and as clinical conditions indicate. When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute. Whenever possible, administer Phytonadione by the subcutaneous route. Related/similar drugs phytonadione, Vitamin K1, Mephyton DOSAGE AND ADMINISTRATION 2.1 Dosing Considerations Phytonadione is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates. Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis.hypoprothrombinemia due to antibacterial therapy.anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives.Phytonadione is indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity: INDICATIONS AND USAGE Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. WARNING - HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USEįatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after intravenous and intramuscular injection of Phytonadione.

Vitamin k1 antidote